PMID- 28588699
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 13
IP  - 6
DP  - 2017 Jun
TI  - Irradiation of peripheral blood mononuclear cells with 7.5 Gy X-rays prior to 
      donor lymphocyte infusion inhibits proliferation while preserving cytotoxicity, 
      and improves the effectiveness of HSCT in patients with hematological 
      malignancies.
PG  - 4101-4108
LID - 10.3892/ol.2017.5966 [doi]
AB  - The aim of the present study was to explore the effect of different X-ray doses 
      on the proliferation and cytotoxic activity of peripheral blood mononuclear cells 
      (PBMCs), particularly lymphocytes, in order to assess whether this reduces the 
      incidence of graft vs. host disease (GVHD) while preserving the graft vs. tumor 
      (GVT) effect in patients with hematological malignancies following hematopoietic 
      stem cell transplantation (HSCT). PBMCs from healthy donors were irradiated with 
      X-rays at doses of 0, 2.5, 5, 7.5, 10, 15, 25 or 50 Gy, and their proliferative 
      activity was determined using a WST-8 assay kit. The cytotoxic activity of 
      non-irradiated PBMCs and PBMCs irradiated with 7.5 Gy X-rays was tested in the 
      leukemic cell line K562 and its Adriamycin-resistant strain K562A using a lactate 
      dehydrogenase assay. The clinical data of 7 patients who received 7.5 Gy 
      X-ray-irradiated PBMC infusions following autologous HSCT were analyzed. PBMCs 
      irradiated with >/=7.5 Gy X-rays exhibited a complete inhibition of proliferation. 
      PBMCs irradiated with 7.5 Gy X-rays exhibited significantly increased cytotoxic 
      activity towards K562 cells compared with K562A cells (P<0.05). There was no 
      significant difference in cytotoxicity between irradiated and non-irradiated 
      PBMCs, irrespective of the target cell, K562 or K562A (P>0.05). Based on the in 
      vitro data, clinical data from patients who received 7.5 Gy X-ray-irradiated PBMC 
      infusions following HSCT between January 2005 and January 2013 were assessed 
      retrospectively. A total of 7 patients were included in the current study. The 
      majority achieved various degrees of remission following donor lymphocyte 
      infusion (DLI) and none suffered from GVHD. This indicates that 7.5 Gy-irradiated 
      PMBCs have a potential application in DLI for the treatment of patients following 
      HSCT. However, further studies on larger patient cohorts are required to assess 
      the clinical potential of 7.5 Gy-irradiated PBMCs for preserving the GVT effect 
      while avoiding GVHD following HSCT.
FAU - Wei, Yong-Qiu
AU  - Wei YQ
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Cen, Xi-Nan
AU  - Cen XN
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Liu, Hui-Hui
AU  - Liu HH
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Sun, Yu-Hua
AU  - Sun YH
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Shi, Yong-Jin
AU  - Shi YJ
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Dong, Yu-Jun
AU  - Dong YJ
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Ren, Han-Yun
AU  - Ren HY
AD  - Department of Hematology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
LA  - eng
PT  - Journal Article
DEP - 20170331
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5452913
OTO - NOTNLM
OT  - cytotoxic activity
OT  - donor lymphocyte infusion
OT  - irradiation
OT  - peripheral blood mononuclear cells
OT  - proliferation inhibition
EDAT- 2017/06/08 06:00
MHDA- 2017/06/08 06:01
PMCR- 2017/03/31
CRDT- 2017/06/08 06:00
PHST- 2016/03/17 00:00 [received]
PHST- 2017/02/03 00:00 [accepted]
PHST- 2017/06/08 06:00 [entrez]
PHST- 2017/06/08 06:00 [pubmed]
PHST- 2017/06/08 06:01 [medline]
PHST- 2017/03/31 00:00 [pmc-release]
AID - OL-0-0-5966 [pii]
AID - 10.3892/ol.2017.5966 [doi]
PST - ppublish
SO  - Oncol Lett. 2017 Jun;13(6):4101-4108. doi: 10.3892/ol.2017.5966. Epub 2017 Mar 
      31.